UNSPSC 51181619: Thiouracil

This classification denotes a nitric oxide synthetase inhibitor with the molecular formula C4H4N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59X161SCYL, chemically known as 2,3-dihydro-2-thioxo-4(1h)-pyrimidinone but generally known as 2-thiouracil, which bears US NIH Compound Identifier 1269845. European Medicines Agency schedules Thiouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15541MIG. Most nations schedule thiouracil under HS 29335990 and SITC 51576.

As of Q4 2014, THIOURACIL remains the US FDA Preferred Term for this commodity. Thiouracil bears US NLM identifiers UMLS ID C0039957 and NCI Concept Code C29856. SMILES: S=C1[NH]C(=O)CC[NH]1.

UNSPSC 51181619 Thiouracil is a Commodity code encompassing specific pharmaceutical active ingredients supplied through state and local cooperative purchasing agreements for use across government health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicited generic multi-source pharmaceuticals including thiouracil and related active ingredients via RFP S1070000015802, due March 26, 2026, to establish contracts effective July 1, 2026. State and local procurement under this code focuses on sourcing individual pharmaceutical products with specific National Drug Codes (NDC) through authorized wholesaler networks—in this case AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—for distribution to participating state agencies, local government facilities, and other public health institutions. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and offer flexible pricing structures (flat price, net price formats, or WAC-minus pricing). Evaluation weighs price competitiveness at 75 percent, with administrative compliance, EDI capability, and pricing format adherence making up the remainder.

MMCAP represents a multi-state cooperative purchasing vehicle spanning Minnesota and participating jurisdictions including Oregon, creating a procurement channel that reaches state departments and local government health systems across multiple regions. The sole recent opportunity identified under this code is the MMCAP generic multi-source pharmaceuticals RFP with a March 26, 2026 response deadline and a February 18, 2026 question cutoff. Vendors must maintain comprehensive insurance including $5,000,000 commercial general liability per occurrence and $2,000,000 network security and privacy liability, and all products must comply with FDA requirements with expiration dates of at least one year from manufacture and a minimum six-month shelf life. The contract term runs two years for new responders with optional MMCAP extensions, or through June 30, 2028 for incumbent amendments. No specific set-aside designations are disclosed; performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials, and awarded vendors pay a 3 percent administrative fee on all contract purchases.